The abstract is read at the publisher; the summary is JClub's.
Comprehensive genomic profiling plus molecularly guided therapy improved progression-free survival versus continued platinum chemotherapy in unfavorable cancer of unknown primary, with median PFS 6.1 vs 4.4 months.
- Why it matters: Unfavorable CUP lacks a known primary site, making standard post-induction chemotherapy decisions difficult and leaving a need for better, biology-informed treatment selection.
- What they did: In the randomized phase II CUPISCO trial (NCT03498521), 436 patients were assigned 3:1 to investigator-chosen MGT after molecular tumor board review or three further chemotherapy cycles, with PFS as the primary endpoint.
- The result: At the December 6, 2024 cutoff, updated results showed HR 0.75 (P=.017) for PFS and no new safety signals, supporting CGP-guided treatment at initial diagnosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.